CSL

News

CSL joins forces with Alentis on claudin candidate

CSL has licensed rights to a potentially first-in-class anti-claudin-1 antibody developed by Alentis in a deal that could be worth up to $1.55bn.

News

UK first country to launch CSL's trivalent flu shot Aujemflu

CSL Seqirus' recently approved trivalent, cell-based influenza vaccine Aujemflu will be part of the UK's 2027/28 immunisation campaign.

News

White House signs pricing deals with nine more pharmas

Nine mid-sized pharmas have signed up for the Trump administration's Most-Favoured Nation (MFN) pricing deals, pledging almost $20bn in investments.

News

Astellas bets on Vir cancer drug, and other licensing deals

Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.

News

Falling flu vaccine sales in US stall CSL's Seqirus spinout

CSL says flu vaccination rates in the US are expected to fall 12% to 14% this year, and have scuppered its plan to spin out its vaccines unit Seqirus.

News

CSL will slash headcount and hive off vaccine business

Facing declines in flu vaccination rates in the US, CSL will spin out its vaccine unit as part of a wider restructuring that will claim 3,000 jobs.

CSL joins forces with Alentis on claudin candidate

UK first country to launch CSL's trivalent flu shot Aujemflu

White House signs pricing deals with nine more pharmas

Astellas bets on Vir cancer drug, and other licensing deals

Falling flu vaccine sales in US stall CSL's Seqirus spinout

CSL will slash headcount and hive off vaccine business

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

CSL

Editor's Picks